TRAP1 Protein

TRAP1 Protein

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">TRAP1 (TNF Receptor-Associated Protein 1)</th></tr>
<tr><td>Gene</td><td>[TRAP1](/genes/trap1)</td></tr>
<tr><td>UniProt ID</td><td>[Q12931](https://www.uniprot.org/uniprot/Q12931)</td></tr>
<tr><td>PDB</td><td>4IYS, 5YKO, 6Z1V</td></tr>
<tr><td>Molecular Weight</td><td>75.5 kDa</td></tr>
<tr><td>Localization</td><td>Mitochondrial matrix, ER, plasma membrane</td></tr>
<tr><td>Family</td><td>Hsp90 family, mitochondrial Hsp90 paralog</td></tr>
<tr><td>Disease</td><td>Cancer, PD, AD, Neuroprotection</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

TRAP1 (TNF receptor-associated protein 1), also known as Hsp75, is a mitochondrial member of the heat shock protein 90 (Hsp90) family. Unlike cytosolic Hsp90, TRAP1 is primarily localized to mitochondria where it regulates protein folding, oxidative phosphorylation, and mitochondrial quality control. TRAP1 has emerged as a neuroprotective protein in Parkinson's disease and other neurodegenerative conditions.

Structure

TRAP1 shares structural homology with Hsp90:

• N-terminal domain (NTD): Contains ATP-binding pocket
• Middle domain (MD): Client protein binding
• C-terminal domain (CTD): Dimerization interface
• Mitochondrial targeting sequence: N-terminal, cleaved after import

TRAP1 Protein

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2">TRAP1 (TNF Receptor-Associated Protein 1)</th></tr>
<tr><td>Gene</td><td>[TRAP1](/genes/trap1)</td></tr>
<tr><td>UniProt ID</td><td>[Q12931](https://www.uniprot.org/uniprot/Q12931)</td></tr>
<tr><td>PDB</td><td>4IYS, 5YKO, 6Z1V</td></tr>
<tr><td>Molecular Weight</td><td>75.5 kDa</td></tr>
<tr><td>Localization</td><td>Mitochondrial matrix, ER, plasma membrane</td></tr>
<tr><td>Family</td><td>Hsp90 family, mitochondrial Hsp90 paralog</td></tr>
<tr><td>Disease</td><td>Cancer, PD, AD, Neuroprotection</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

TRAP1 (TNF receptor-associated protein 1), also known as Hsp75, is a mitochondrial member of the heat shock protein 90 (Hsp90) family. Unlike cytosolic Hsp90, TRAP1 is primarily localized to mitochondria where it regulates protein folding, oxidative phosphorylation, and mitochondrial quality control. TRAP1 has emerged as a neuroprotective protein in Parkinson's disease and other neurodegenerative conditions.

Structure

TRAP1 shares structural homology with Hsp90:

• N-terminal domain (NTD): Contains ATP-binding pocket
• Middle domain (MD): Client protein binding
• C-terminal domain (CTD): Dimerization interface
• Mitochondrial targeting sequence: N-terminal, cleaved after import

• Forms homodimers via C-terminal domain
• ATPase activity drives conformational changes
• Lacks the charged linker region present in Hsp90
• Unique substrate specificity compared to Hsp90α/β[@lavery2014]

Normal Function

TRAP1 has multiple mitochondrial functions:

TRAP1 in the neuroprotection pathway:

• Phosphorylated by PINK1 at S228 → Enhanced activity
• Reduces ROS from Complex I
• Protects dopaminergic [neurons](/entities/neurons)

Role in Neurodegeneration

Parkinson's Disease

TRAP1 is a key neuroprotective factor in PD[@pridgeon2007]:

PINK1-Parkin pathway:

• PINK1 phosphorylates and activates TRAP1
• TRAP1 reduces oxidative stress
• Compensates for PINK1/Parkin deficiency
• Loss of TRAP1 increases PD vulnerability

TRAP1 deficiency:

• Increased susceptibility to MPTP/MPP⁺ toxicity
• Enhanced [α-synuclein](/proteins/alpha-synuclein) aggregation
• Accelerated dopaminergic neuron loss

Alzheimer's Disease

TRAP1 in AD:

• [Aβ](/proteins/amyloid-beta) toxicity: TRAP1 may protect against Aβ-induced mitochondrial dysfunction
• Reduced expression: Observed in AD brain mitochondria
• Complex I protection: May preserve OXPHOS function

Cancer Connection

TRAP1 is overexpressed in many cancers:

• Promotes the "Warburg effect" (glycolytic shift)
• Protects from apoptosis
• Target for cancer therapy (TRAP1 inhibitors)
• Must balance neuroprotection vs. oncogenic effects[@altieri2014]

Therapeutic Targeting

| Strategy | Mechanism | Status |
|----------|-----------|--------|
| TRAP1 activators | Enhance chaperone activity | Preclinical |
| Mitochondrial Hsp90 inhibitors | (Cancer context) | Preclinical |
| PINK1-TRAP1 axis | Upstream activation | Research |
| Mitochondria-targeted antioxidants | Complementary | Clinical |

Therapeutic considerations:

• TRAP1 activation: Neuroprotective, but may promote cancer
• Selective targeting to brain needed
• Combination with mitochondrial enhancers

See Also

• [Hsp90 - Cytosolic family member](/proteins/hsp90)
• [PINK1 - TRAP1 kinase](/proteins/pink1-protein)
• [Parkin - Mitophagy E3 ligase](/proteins/parkin)
• Cyclophilin D - mPTP regulator
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)

References